Preeclampsia Diagnostics Market By Diagnostic Test Type (Blood Test, Urine Test, Imaging Tests), By Technology (Immunoassay Technology, Point-of-Care Testing, Ultrasound Technology), By Application (Prenatal Care, High-Risk Pregnancy Management), By End-User (Hospitals, Diagnostic Laboratories), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Preeclampsia Diagnostics Market was valued at USD 1.1 billion in 2024-e and will surpass USD 1.8 billion by 2030; growing at a CAGR of 8.9% during 2025 - 2030.

The preeclampsia diagnostics market is expanding due to the growing need for early detection and management of preeclampsia, a potentially life-threatening condition during pregnancy. Preeclampsia, characterized by high blood pressure and organ damage, requires careful monitoring to prevent complications for both the mother and the fetus. Early diagnosis is crucial, as timely intervention can reduce maternal and neonatal morbidity and mortality. With the rise in high-risk pregnancies and advancements in diagnostic technologies, the market is seeing increased demand for efficient and accurate diagnostic tools. Healthcare providers are focusing on improving prenatal care and high-risk pregnancy management through advanced diagnostic solutions, contributing to the growth of this market.

Technological advancements, particularly in point-of-care (POC) testing and imaging, are driving market growth. The need for non-invasive, rapid, and reliable diagnostic tools is pushing innovations in diagnostic tests and technologies. As healthcare systems aim to enhance maternal and fetal health outcomes, there is a growing emphasis on integrating advanced technologies into routine prenatal care to enable faster diagnosis and better management of preeclampsia. The increasing prevalence of preeclampsia, especially in developed regions with aging populations and rising obesity rates, is further driving the demand for effective diagnostics and timely interventions.

Blood Test Diagnostic Type is Largest Owing to Early Detection and Convenience

Blood tests are the largest diagnostic type in the preeclampsia diagnostics market, owing to their ability to offer early detection and convenience in clinical settings. Blood biomarkers such as sFlt-1, PlGF (placental growth factor), and uric acid levels are commonly used to identify signs of preeclampsia. These tests enable healthcare providers to assess the risk of preeclampsia development in pregnant women, allowing for timely intervention and better management of the condition. Blood tests are widely used because they are minimally invasive, relatively easy to perform, and can be integrated into routine prenatal care visits. Furthermore, advancements in blood biomarker research are continuously improving the accuracy and predictive power of these tests.

The ability to diagnose preeclampsia through blood tests has revolutionized prenatal care by offering a more convenient and effective alternative to traditional diagnostic methods. Given that preeclampsia often develops gradually, the use of blood tests allows healthcare providers to monitor potential complications at an early stage, thereby enhancing maternal and fetal health outcomes. As the demand for early detection continues to grow, blood tests will remain the largest diagnostic test type in the preeclampsia diagnostics market, particularly in high-risk pregnancy management.

Point-of-Care Testing Technology is Fastest Growing Owing to Convenience and Rapid Results

Point-of-care (POC) testing is the fastest-growing technology in the preeclampsia diagnostics market, primarily due to its convenience, speed, and ability to deliver immediate results. POC tests enable healthcare providers to diagnose preeclampsia at the point of care, allowing for rapid intervention without the need for patients to wait for lab results. This technology is especially beneficial in settings where quick decisions are crucial, such as in remote areas or during emergency care. With the growing demand for faster and more accessible diagnostics, POC testing is increasingly being adopted for preeclampsia detection.

POC testing technologies are advancing rapidly, offering portable devices and easy-to-use diagnostic tools that can be used by healthcare professionals in a variety of settings. These technologies provide results within minutes, enabling doctors to make real-time decisions about patient care. The growing adoption of POC testing in prenatal care is driven by the need for efficient, on-the-spot diagnostics that improve patient outcomes. As a result, point-of-care testing is expected to be the fastest-growing technology segment in the preeclampsia diagnostics market, driven by the increasing emphasis on convenient and rapid diagnostics.

Prenatal Care Application is Largest Owing to Regular Monitoring of Pregnancy

The prenatal care application is the largest segment in the preeclampsia diagnostics market, driven by the routine monitoring and early detection of complications during pregnancy. Prenatal care involves regular check-ups to monitor both maternal and fetal health, with early detection of preeclampsia being a key component. By using diagnostic tests such as blood tests and point-of-care testing, healthcare providers can identify preeclampsia early, which is essential for minimizing risks to both the mother and the baby. Regular screening during prenatal visits helps ensure that women at risk of preeclampsia receive timely medical attention, reducing the likelihood of severe complications.

The focus on prenatal care has intensified in recent years due to the increasing awareness of maternal and fetal health and the importance of early detection of pregnancy-related complications. With advancements in diagnostic technologies, prenatal care has become more comprehensive and effective, contributing to the growing demand for preeclampsia diagnostics. As the healthcare industry continues to prioritize the health of pregnant women and their babies, prenatal care will remain the largest application for preeclampsia diagnostics.

Hospitals End-User is Largest Owing to Primary Healthcare Provider for Pregnancy Care

Hospitals are the largest end-user segment in the preeclampsia diagnostics market, owing to their role as primary healthcare providers for pregnancy care. Hospitals are equipped with the necessary infrastructure and medical expertise to conduct comprehensive prenatal check-ups, including diagnostic tests for preeclampsia. Hospital-based labs and specialized departments such as obstetrics and gynecology routinely conduct screenings for high-risk pregnancies, making them the primary consumers of preeclampsia diagnostic tools. Moreover, hospitals are equipped to handle complicated cases of preeclampsia, providing a broad range of diagnostic services to monitor maternal and fetal health.

The growth of hospital-based prenatal care, along with increasing government and private sector investments in maternal health, ensures that hospitals will remain the largest end-user segment for preeclampsia diagnostics. The integration of advanced diagnostic technologies into hospital settings is expected to enhance the efficiency of preeclampsia detection and management, further driving the demand for diagnostic tools in this segment.

North America Region is Largest Owing to Advanced Healthcare Infrastructure

North America is the largest region in the preeclampsia diagnostics market, owing to its advanced healthcare infrastructure, high awareness of maternal health, and widespread use of diagnostic technologies. The United States, in particular, has a well-established healthcare system that prioritizes maternal and prenatal care, resulting in a high demand for preeclampsia diagnostic tools. In addition, North America’s healthcare providers have access to cutting-edge diagnostic technologies, such as point-of-care testing and blood biomarkers, which are widely used to detect preeclampsia early in high-risk pregnancies. The region’s focus on reducing maternal mortality rates and improving pregnancy outcomes further supports the demand for advanced diagnostics.

The well-developed healthcare infrastructure in North America, along with a high level of research and innovation in maternal health, makes it the largest market for preeclampsia diagnostics. The region’s emphasis on early diagnosis and intervention in high-risk pregnancies ensures that North America will continue to lead the global market for preeclampsia diagnostics.

Leading Companies and Competitive Landscape

The leading companies in the preeclampsia diagnostics market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific, among others. These companies are key players in developing advanced diagnostic solutions, including immunoassay tests, point-of-care devices, and imaging technologies, that aid in the early detection of preeclampsia. The competitive landscape is marked by continuous innovation, with companies investing in research and development to improve the accuracy and convenience of diagnostic tests. Strategic partnerships, acquisitions, and the launch of new products are common strategies employed by these companies to maintain their competitive position.

As the market evolves, companies are focusing on expanding their product portfolios to include more accessible and efficient diagnostic solutions, particularly in the point-of-care and blood test segments. With increasing demand for rapid, accurate diagnostics, the competitive landscape remains dynamic, with major players continuously striving to meet the needs of healthcare providers and improve outcomes for pregnant women at risk of preeclampsia.

Recent Developments:

• In December 2024, Roche Diagnostics launched a new blood test aimed at early detection of preeclampsia biomarkers.
• In November 2024, Abbott Laboratories introduced an AI-driven diagnostic tool for detecting preeclampsia in prenatal care settings.
• In October 2024, Medtronic unveiled a wearable device for continuous monitoring of blood pressure to help detect preeclampsia early.
• In September 2024, Siemens Healthineers expanded its point-of-care testing portfolio with a new preeclampsia detection device.
• In August 2024, GE Healthcare introduced an advanced ultrasound system designed to detect signs of preeclampsia and monitor fetal health.

List of Leading Companies:

• Roche Diagnostics
• Siemens Healthineers
• Abbott Laboratories
• Thermo Fisher Scientific
• PerkinElmer
• Bio-Rad Laboratories
• Quidel Corporation
• LabCorp
• Philips Healthcare
• Medtronic
• GE Healthcare
• Beckman Coulter
• Hologic, Inc.
• Fujifilm Holdings Corporation
• Becton Dickinson and Company

Report Scope: